Study of FWY003 for geographic atrophy in age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years of age or older.
- You must have geographic atrophy in at least one eye, with the affected area between 2.5 and 17.5 square millimeters.
- Your vision in the study eye must be at least 20/200.
- You cannot have had certain eye surgeries within the last 3 months.
- If you have had any cell or gene therapy in either eye, you are not eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
Hear when a new Geographic Atrophy Secondary to Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.